Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,601 signal articles · 135 in last 24h · 155,365 total before filter · latest 2h ago
135last 24h
852last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro192Earnings102M&A125Regulatory20Product22Analyst19
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
Starbucks vs Chipotle: Two Restaurant Titans, Two Playbooks, Only One Winner
24/7 Wall St.82d agoneutral
Starbucks vs Chipotle: Two Restaurant Titans, Two Playbooks, Only One Winner

Starbucks (NASDAQ:SBUX) and Chipotle Mexican Grill (NYSE:CMG) just delivered two of the most instructive turnaround updates in restaurants. Starbucks posted its clearest inflection yet under Brian Niccol. Chipotle, still working through a full year of negative comps, leaned harder on unit growth and menu innovation. Same sector, two very different scoreboards. Coffee Traffic Comes Back. ... Starbucks vs Chipotle: Two Restaurant Titans, Two Playbooks, Only One Winner

Wall Street's $200 billion IPO wave threatens sell-off
TheStreet82d agobearish
Wall Street's $200 billion IPO wave threatens sell-off

SpaceX, Anthropic, and OpenAI are collectively moving toward public offerings that could rank among the most valuable stock sales ever completed. The flood of new shares entering the market creates selling pressure on stocks that investors already have in their portfolios. Academic research ...

Investing.com84d agoneutral
Will a DT/TMUS merger really go ahead?

Investing.com -- Deutsche Telekom’s recent share price decline appears overdone, according to UBS, which argues that investor concerns over a potential merger with T-Mobile US and rising competition in the U.S. wireless market have overshadowed the company’s strong operating performance.

CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology
Exec Edge85d agoneutral
CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular […] The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.

Jersey Mike's Subs files for IPO, targets NYSE listing
Proactive85d agoneutral
Jersey Mike's Subs files for IPO, targets NYSE listing

Jersey Mike's Subs, the sandwich chain backed by Blackstone, has filed for an initial public offering, seeking to capitalize on a rebound in the United States IPO market. The company plans to list its Class A common stock on the New York Stock Exchange under the ticker symbol ‘JMKE.’ The...

Mark Zuckerberg Almost Made a Disastrous Acquisition. Walking Away From Kalshi May Have Been His Best Bet of 2026.
24/7 Wall St.85d agoneutral
Mark Zuckerberg Almost Made a Disastrous Acquisition. Walking Away From Kalshi May Have Been His Best Bet of 2026.

Mark Zuckerberg just dodged a bullet. Zuckerberg, whom speculators give 32% odds of becoming the next trillionaire, came eerily close to steering Meta Platforms (NASDAQ:META) into one of the most legally and ethically fraught corners of consumer tech. According to NPR reporting from June 30, Zuckerberg personally floated an acquisition of prediction market platform Kalshi. ... Mark Zuckerberg Almost Made a Disastrous Acquisition. Walking Away From Kalshi May Have Been His Best Bet of 2026.